The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour
Mouse spontaneous climbing behaviour was dose-dependently inhibited by putative dopamine agonists administered subcutaneously (s.c.) or directly into the mesolimbic nucleus accumbens. ED 50 values for s.c. administrations of apomorphine, bromocriptine, DPI, 3-PPP and DK118 (5-hydroxy-6-methyl-2-di-n...
Gespeichert in:
| Veröffentlicht in: | European journal of pharmacology 1983-12, Vol.96 (3), p.201-210 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 210 |
|---|---|
| container_issue | 3 |
| container_start_page | 201 |
| container_title | European journal of pharmacology |
| container_volume | 96 |
| creator | Costall, Brenda Eniojukan, Joshua F. Naylor, Robert J. |
| description | Mouse spontaneous climbing behaviour was dose-dependently inhibited by putative dopamine agonists administered subcutaneously (s.c.) or directly into the mesolimbic nucleus accumbens. ED
50 values for s.c. administrations of apomorphine, bromocriptine, DPI, 3-PPP and DK118 (5-hydroxy-6-methyl-2-di-n-propylaminotetralin) were 0.01, 0.26, 0.17, 0.24 and 0.0004 mg/kg respectively, and for intra-accumbens apomorphine, DPI, bromocriptine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were 0.21, 0.22, 7.5, 0.00034 and 0.000034 μg respectively. Dose-dependent reduction in motor inhibitory potential/motor facilitation was also recorded for higher doses of apomorphine given s.c., or for apomorphine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin given intra-accumbens (ED
50 values to restore spontaneous climbing to control values were 4.1, 4.2 and 0.8 μg respectively). The motor inhibitory actions of apomorphine, 3-PPP, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were antagonised by (-)-sulpiride, but not by yohimbine or prazosin. The actions of DPI were yohimbine-sensitive. Whilst the motor inhibition caused by s.c. bromocriptine was neuroleptic-sensitive, that observed on intra-accumbens injection was resistant to all antagonists. The intra-accumbens effectivenes of the dopamine agonists could not be mimicked by injections above the nucleus accumbens (into the head of the caudate-putamen complex) or below the nucleus accumbens (into the tuberculum olfactorium) (with the exception of the effectiveness of bromcriptine administered into the tuberculum olfactorium). It is suggested that the actions of ‘dopamine agonists’ to both inhibits and facilitate mouse spontaneous climbing behaviour involves an action in the mesolimbic nucleus accumbens.Whilst the mechanism involved are generally neuroleptic-sensitive,
α
2-adrenoceptor (for DPI) and other unidentified mechanisms (for bromocriptine) may also be important. |
| doi_str_mv | 10.1016/0014-2999(83)90309-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80895918</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0014299983903096</els_id><sourcerecordid>80895918</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-9c8475b080696b2b8b113d336b665bb41c7121fa3d2846371f2acfbbe109977b3</originalsourceid><addsrcrecordid>eNp9kcGOFCEQhonRrLOrb6AJB2P00ApNNw0XE7Nx1WQTL-uZAA07ZbphBHrMvJmPJzM9maMniqrvr1T-H6FXlHyghPKPhNCuaaWU7wR7LwkjsuFP0IaKQTZkoO1TtLkgz9F1zr8IIb1s-yt0xbuWy4Fv0N-HrcOzy3GC2YDFYbGTWzLW1i6zcSFjyNgmKGD1NB0whH2c9m7Ef6BscTmJR9AFYsDRr41YYqrgFgzU6oB1GLHXFiYo-tRw3jtb8lEwxp2eITisH2OAfGyGumHJDuddDEUHVz_Yns4Lj9i4rd5DXNIL9MzrKbuX5_cG_bz78nD7rbn_8fX77ef7xjLBSyOt6IbeEEG45KY1wlDKRsa44bw3pqO2OkW9ZmMrOs4G6lttvTGOEimHwbAb9Hbdu0vx9-JyUTNk66ZpvUwJImQvqahgt4I2xZyT82qXYNbpoChRx8DUMQ11TEMJpk6BKV5lr8_7F1OtvIjOCdX5m_Nc5xqBTzpYyBdMiL5bsU8r5qoXe3BJZQsu2BpOql6rMcL_7_gHVp-22w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80895918</pqid></control><display><type>article</type><title>The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Costall, Brenda ; Eniojukan, Joshua F. ; Naylor, Robert J.</creator><creatorcontrib>Costall, Brenda ; Eniojukan, Joshua F. ; Naylor, Robert J.</creatorcontrib><description>Mouse spontaneous climbing behaviour was dose-dependently inhibited by putative dopamine agonists administered subcutaneously (s.c.) or directly into the mesolimbic nucleus accumbens. ED
50 values for s.c. administrations of apomorphine, bromocriptine, DPI, 3-PPP and DK118 (5-hydroxy-6-methyl-2-di-n-propylaminotetralin) were 0.01, 0.26, 0.17, 0.24 and 0.0004 mg/kg respectively, and for intra-accumbens apomorphine, DPI, bromocriptine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were 0.21, 0.22, 7.5, 0.00034 and 0.000034 μg respectively. Dose-dependent reduction in motor inhibitory potential/motor facilitation was also recorded for higher doses of apomorphine given s.c., or for apomorphine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin given intra-accumbens (ED
50 values to restore spontaneous climbing to control values were 4.1, 4.2 and 0.8 μg respectively). The motor inhibitory actions of apomorphine, 3-PPP, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were antagonised by (-)-sulpiride, but not by yohimbine or prazosin. The actions of DPI were yohimbine-sensitive. Whilst the motor inhibition caused by s.c. bromocriptine was neuroleptic-sensitive, that observed on intra-accumbens injection was resistant to all antagonists. The intra-accumbens effectivenes of the dopamine agonists could not be mimicked by injections above the nucleus accumbens (into the head of the caudate-putamen complex) or below the nucleus accumbens (into the tuberculum olfactorium) (with the exception of the effectiveness of bromcriptine administered into the tuberculum olfactorium). It is suggested that the actions of ‘dopamine agonists’ to both inhibits and facilitate mouse spontaneous climbing behaviour involves an action in the mesolimbic nucleus accumbens.Whilst the mechanism involved are generally neuroleptic-sensitive,
α
2-adrenoceptor (for DPI) and other unidentified mechanisms (for bromocriptine) may also be important.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/0014-2999(83)90309-6</identifier><identifier>PMID: 6426976</identifier><identifier>CODEN: EJPHAZ</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Animals ; Apomorphine - pharmacology ; Behavior, Animal - drug effects ; Biological and medical sciences ; Catecholaminergic system ; Dopamine - administration & dosage ; Dopamine - pharmacology ; Dopamine agonists ; Dose-Response Relationship, Drug ; Female ; Medical sciences ; Mice ; Mice, Inbred Strains ; Motor Activity - drug effects ; Motor facilitation ; Motor inhibition ; Mouse spontaneous climbing behaviour ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Nucleus accumbens ; Nucleus Accumbens - drug effects ; Pharmacology. Drug treatments ; Prazosin - pharmacology ; Septal Nuclei - drug effects ; Sulpiride - pharmacology ; Tetrahydronaphthalenes - pharmacology</subject><ispartof>European journal of pharmacology, 1983-12, Vol.96 (3), p.201-210</ispartof><rights>1983</rights><rights>1985 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-9c8475b080696b2b8b113d336b665bb41c7121fa3d2846371f2acfbbe109977b3</citedby><cites>FETCH-LOGICAL-c386t-9c8475b080696b2b8b113d336b665bb41c7121fa3d2846371f2acfbbe109977b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0014299983903096$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8854976$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6426976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costall, Brenda</creatorcontrib><creatorcontrib>Eniojukan, Joshua F.</creatorcontrib><creatorcontrib>Naylor, Robert J.</creatorcontrib><title>The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Mouse spontaneous climbing behaviour was dose-dependently inhibited by putative dopamine agonists administered subcutaneously (s.c.) or directly into the mesolimbic nucleus accumbens. ED
50 values for s.c. administrations of apomorphine, bromocriptine, DPI, 3-PPP and DK118 (5-hydroxy-6-methyl-2-di-n-propylaminotetralin) were 0.01, 0.26, 0.17, 0.24 and 0.0004 mg/kg respectively, and for intra-accumbens apomorphine, DPI, bromocriptine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were 0.21, 0.22, 7.5, 0.00034 and 0.000034 μg respectively. Dose-dependent reduction in motor inhibitory potential/motor facilitation was also recorded for higher doses of apomorphine given s.c., or for apomorphine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin given intra-accumbens (ED
50 values to restore spontaneous climbing to control values were 4.1, 4.2 and 0.8 μg respectively). The motor inhibitory actions of apomorphine, 3-PPP, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were antagonised by (-)-sulpiride, but not by yohimbine or prazosin. The actions of DPI were yohimbine-sensitive. Whilst the motor inhibition caused by s.c. bromocriptine was neuroleptic-sensitive, that observed on intra-accumbens injection was resistant to all antagonists. The intra-accumbens effectivenes of the dopamine agonists could not be mimicked by injections above the nucleus accumbens (into the head of the caudate-putamen complex) or below the nucleus accumbens (into the tuberculum olfactorium) (with the exception of the effectiveness of bromcriptine administered into the tuberculum olfactorium). It is suggested that the actions of ‘dopamine agonists’ to both inhibits and facilitate mouse spontaneous climbing behaviour involves an action in the mesolimbic nucleus accumbens.Whilst the mechanism involved are generally neuroleptic-sensitive,
α
2-adrenoceptor (for DPI) and other unidentified mechanisms (for bromocriptine) may also be important.</description><subject>Animals</subject><subject>Apomorphine - pharmacology</subject><subject>Behavior, Animal - drug effects</subject><subject>Biological and medical sciences</subject><subject>Catecholaminergic system</subject><subject>Dopamine - administration & dosage</subject><subject>Dopamine - pharmacology</subject><subject>Dopamine agonists</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Motor Activity - drug effects</subject><subject>Motor facilitation</subject><subject>Motor inhibition</subject><subject>Mouse spontaneous climbing behaviour</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Nucleus accumbens</subject><subject>Nucleus Accumbens - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Prazosin - pharmacology</subject><subject>Septal Nuclei - drug effects</subject><subject>Sulpiride - pharmacology</subject><subject>Tetrahydronaphthalenes - pharmacology</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1983</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcGOFCEQhonRrLOrb6AJB2P00ApNNw0XE7Nx1WQTL-uZAA07ZbphBHrMvJmPJzM9maMniqrvr1T-H6FXlHyghPKPhNCuaaWU7wR7LwkjsuFP0IaKQTZkoO1TtLkgz9F1zr8IIb1s-yt0xbuWy4Fv0N-HrcOzy3GC2YDFYbGTWzLW1i6zcSFjyNgmKGD1NB0whH2c9m7Ef6BscTmJR9AFYsDRr41YYqrgFgzU6oB1GLHXFiYo-tRw3jtb8lEwxp2eITisH2OAfGyGumHJDuddDEUHVz_Yns4Lj9i4rd5DXNIL9MzrKbuX5_cG_bz78nD7rbn_8fX77ef7xjLBSyOt6IbeEEG45KY1wlDKRsa44bw3pqO2OkW9ZmMrOs4G6lttvTGOEimHwbAb9Hbdu0vx9-JyUTNk66ZpvUwJImQvqahgt4I2xZyT82qXYNbpoChRx8DUMQ11TEMJpk6BKV5lr8_7F1OtvIjOCdX5m_Nc5xqBTzpYyBdMiL5bsU8r5qoXe3BJZQsu2BpOql6rMcL_7_gHVp-22w</recordid><startdate>19831223</startdate><enddate>19831223</enddate><creator>Costall, Brenda</creator><creator>Eniojukan, Joshua F.</creator><creator>Naylor, Robert J.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19831223</creationdate><title>The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour</title><author>Costall, Brenda ; Eniojukan, Joshua F. ; Naylor, Robert J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-9c8475b080696b2b8b113d336b665bb41c7121fa3d2846371f2acfbbe109977b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1983</creationdate><topic>Animals</topic><topic>Apomorphine - pharmacology</topic><topic>Behavior, Animal - drug effects</topic><topic>Biological and medical sciences</topic><topic>Catecholaminergic system</topic><topic>Dopamine - administration & dosage</topic><topic>Dopamine - pharmacology</topic><topic>Dopamine agonists</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Motor Activity - drug effects</topic><topic>Motor facilitation</topic><topic>Motor inhibition</topic><topic>Mouse spontaneous climbing behaviour</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Nucleus accumbens</topic><topic>Nucleus Accumbens - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Prazosin - pharmacology</topic><topic>Septal Nuclei - drug effects</topic><topic>Sulpiride - pharmacology</topic><topic>Tetrahydronaphthalenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costall, Brenda</creatorcontrib><creatorcontrib>Eniojukan, Joshua F.</creatorcontrib><creatorcontrib>Naylor, Robert J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costall, Brenda</au><au>Eniojukan, Joshua F.</au><au>Naylor, Robert J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>1983-12-23</date><risdate>1983</risdate><volume>96</volume><issue>3</issue><spage>201</spage><epage>210</epage><pages>201-210</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><coden>EJPHAZ</coden><abstract>Mouse spontaneous climbing behaviour was dose-dependently inhibited by putative dopamine agonists administered subcutaneously (s.c.) or directly into the mesolimbic nucleus accumbens. ED
50 values for s.c. administrations of apomorphine, bromocriptine, DPI, 3-PPP and DK118 (5-hydroxy-6-methyl-2-di-n-propylaminotetralin) were 0.01, 0.26, 0.17, 0.24 and 0.0004 mg/kg respectively, and for intra-accumbens apomorphine, DPI, bromocriptine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were 0.21, 0.22, 7.5, 0.00034 and 0.000034 μg respectively. Dose-dependent reduction in motor inhibitory potential/motor facilitation was also recorded for higher doses of apomorphine given s.c., or for apomorphine, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin given intra-accumbens (ED
50 values to restore spontaneous climbing to control values were 4.1, 4.2 and 0.8 μg respectively). The motor inhibitory actions of apomorphine, 3-PPP, DK118 and 2-di-n-propylamino-5,6-dihydroxytetralin were antagonised by (-)-sulpiride, but not by yohimbine or prazosin. The actions of DPI were yohimbine-sensitive. Whilst the motor inhibition caused by s.c. bromocriptine was neuroleptic-sensitive, that observed on intra-accumbens injection was resistant to all antagonists. The intra-accumbens effectivenes of the dopamine agonists could not be mimicked by injections above the nucleus accumbens (into the head of the caudate-putamen complex) or below the nucleus accumbens (into the tuberculum olfactorium) (with the exception of the effectiveness of bromcriptine administered into the tuberculum olfactorium). It is suggested that the actions of ‘dopamine agonists’ to both inhibits and facilitate mouse spontaneous climbing behaviour involves an action in the mesolimbic nucleus accumbens.Whilst the mechanism involved are generally neuroleptic-sensitive,
α
2-adrenoceptor (for DPI) and other unidentified mechanisms (for bromocriptine) may also be important.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>6426976</pmid><doi>10.1016/0014-2999(83)90309-6</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2999 |
| ispartof | European journal of pharmacology, 1983-12, Vol.96 (3), p.201-210 |
| issn | 0014-2999 1879-0712 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80895918 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Animals Apomorphine - pharmacology Behavior, Animal - drug effects Biological and medical sciences Catecholaminergic system Dopamine - administration & dosage Dopamine - pharmacology Dopamine agonists Dose-Response Relationship, Drug Female Medical sciences Mice Mice, Inbred Strains Motor Activity - drug effects Motor facilitation Motor inhibition Mouse spontaneous climbing behaviour Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Nucleus accumbens Nucleus Accumbens - drug effects Pharmacology. Drug treatments Prazosin - pharmacology Septal Nuclei - drug effects Sulpiride - pharmacology Tetrahydronaphthalenes - pharmacology |
| title | The mesolimbic nucleus accumbens is critically involved with the mediation of the motor inhibitory and facilitatory effects of dopamine agonists on mouse spontaneous climbing behaviour |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A59%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20mesolimbic%20nucleus%20accumbens%20is%20critically%20involved%20with%20the%20mediation%20of%20the%20motor%20inhibitory%20and%20facilitatory%20effects%20of%20dopamine%20agonists%20on%20mouse%20spontaneous%20climbing%20behaviour&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Costall,%20Brenda&rft.date=1983-12-23&rft.volume=96&rft.issue=3&rft.spage=201&rft.epage=210&rft.pages=201-210&rft.issn=0014-2999&rft.eissn=1879-0712&rft.coden=EJPHAZ&rft_id=info:doi/10.1016/0014-2999(83)90309-6&rft_dat=%3Cproquest_cross%3E80895918%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80895918&rft_id=info:pmid/6426976&rft_els_id=0014299983903096&rfr_iscdi=true |